A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)

Gender PreferenceNone
Age Group0 - 99 years
Research Start DateJune 23, 2009
Research End DateJune 23, 2019
Principal InvestigatorAyman El-Sheikh, MD
Description

Participants in this study have been diagnosed with acute lymphoblastic leukemia (ALL) or a cancer of the immune system tissue. The purpose of this study is test effectiveness of adding a drug called bortezomib to the standard therapy for relapsed ALL. Approximately 6 people will take part in this study conducted by investigators at the University of Iowa. Study involvement will last approximately 15 weeks.

Contact Info

Julie de la Garza, 319-356-3749

Keywordsspan itemProp='description'>acute lymphoblastic leukemia (ALL) ; bortezomib ; cancer ; el-sheikh ; immune system tissue ; IRB#200904794 ; pediatric ;